HUP0304085A3 - The citrate salt of 5,8,14-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof - Google Patents

The citrate salt of 5,8,14-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Info

Publication number
HUP0304085A3
HUP0304085A3 HU0304085A HUP0304085A HUP0304085A3 HU P0304085 A3 HUP0304085 A3 HU P0304085A3 HU 0304085 A HU0304085 A HU 0304085A HU P0304085 A HUP0304085 A HU P0304085A HU P0304085 A3 HUP0304085 A3 HU P0304085A3
Authority
HU
Hungary
Prior art keywords
triazatetracyclo
pentaene
hexadeca
pharmaceutical compositions
citrate salt
Prior art date
Application number
HU0304085A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0304085(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HUP0304085A2 publication Critical patent/HUP0304085A2/hu
Publication of HUP0304085A3 publication Critical patent/HUP0304085A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
HU0304085A 2001-05-14 2002-04-26 The citrate salt of 5,8,14-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof HUP0304085A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29086301P 2001-05-14 2001-05-14
PCT/IB2002/001450 WO2002092597A1 (en) 2001-05-14 2002-04-26 The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.0?2,11.04.9¿)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
HUP0304085A2 HUP0304085A2 (en) 2004-04-28
HUP0304085A3 true HUP0304085A3 (en) 2005-09-28

Family

ID=23117854

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0304085A HUP0304085A3 (en) 2001-05-14 2002-04-26 The citrate salt of 5,8,14-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

Country Status (37)

Country Link
US (1) US6787549B2 (enExample)
EP (1) EP1390366B1 (enExample)
JP (1) JP4137645B2 (enExample)
KR (1) KR20040008175A (enExample)
CN (1) CN1509288A (enExample)
AP (1) AP1429A (enExample)
AR (1) AR035889A1 (enExample)
AT (1) ATE303386T1 (enExample)
BG (1) BG108344A (enExample)
CA (1) CA2446988A1 (enExample)
CZ (1) CZ20032917A3 (enExample)
DE (1) DE60205888T2 (enExample)
DO (1) DOP2002000390A (enExample)
DZ (1) DZ3503A1 (enExample)
EA (1) EA005529B1 (enExample)
EE (1) EE200300557A (enExample)
ES (1) ES2245731T3 (enExample)
GT (1) GT200200081A (enExample)
HR (1) HRP20030911A2 (enExample)
HU (1) HUP0304085A3 (enExample)
IL (1) IL157874A0 (enExample)
IS (1) IS6956A (enExample)
MA (1) MA27021A1 (enExample)
MX (1) MXPA03010365A (enExample)
MY (1) MY134123A (enExample)
NO (1) NO20035035L (enExample)
NZ (1) NZ528209A (enExample)
OA (1) OA12600A (enExample)
PA (1) PA8545001A1 (enExample)
PE (1) PE20021095A1 (enExample)
PL (1) PL366774A1 (enExample)
SK (1) SK13372003A3 (enExample)
TN (1) TNSN03112A1 (enExample)
UA (1) UA73421C2 (enExample)
UY (1) UY27287A1 (enExample)
WO (1) WO2002092597A1 (enExample)
ZA (1) ZA200307234B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122008000038I1 (de) * 1997-12-31 2008-11-13 Pfizer Prod Inc Arylkondensierte azapolycyclische derivate
AU2002351008B2 (en) * 2001-11-30 2007-07-12 Pfizer Products Inc. Pharmaceutical compositions of 5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
BRPI0410219A (pt) * 2003-05-20 2006-05-09 Pfizer Prod Inc composições farmacêuticas de vareniclina
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
BRPI0718600A2 (pt) * 2006-11-09 2013-12-10 Pfizer Prod Inc Polimorfos de intermediários nicotínicos.
US8440825B2 (en) 2008-03-06 2013-05-14 Medichem S.A. Fumaric acid salt of varenicline
WO2009143347A2 (en) 2008-05-22 2009-11-26 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
MY160005A (en) * 2008-12-11 2017-02-15 Cti Biopharma Corp 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
WO2010143070A2 (en) 2009-06-10 2010-12-16 Actavis Group Ptc Ehf Amorphous varenicline tartrate co-precipitates
RU2012102052A (ru) 2009-06-22 2013-11-20 Тева Фармасьютикал Индастриз Лтд. Твердые формы солей варениклина и способы их получения
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
PL2837632T3 (pl) 2012-04-13 2017-01-31 Lianyungang Jinkang Hexin Pharmaceutical Co. Ltd. Pochodne triazabicyklo[3.2.1]oktanu użyteczne do leczenia chorób proliferacyjnych
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
EP3756653A1 (en) 2019-06-28 2020-12-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Microparticulate varenicline citrate
US20230105412A1 (en) * 2020-03-16 2023-04-06 Jinkun Huang 5-ht3 receptor modulator, the crystalline form, methods of making, and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122008000038I1 (de) * 1997-12-31 2008-11-13 Pfizer Prod Inc Arylkondensierte azapolycyclische derivate
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
TNSN03112A1 (fr) 2005-12-23
JP2004529186A (ja) 2004-09-24
MY134123A (en) 2007-11-30
DZ3503A1 (enExample) 2002-11-21
JP4137645B2 (ja) 2008-08-20
MA27021A1 (fr) 2004-12-20
SK13372003A3 (sk) 2004-08-03
EA200301120A1 (ru) 2004-02-26
DE60205888T2 (de) 2006-07-06
OA12600A (en) 2006-06-09
HUP0304085A2 (en) 2004-04-28
US6787549B2 (en) 2004-09-07
PA8545001A1 (es) 2003-09-05
DE60205888D1 (de) 2005-10-06
CN1509288A (zh) 2004-06-30
NO20035035D0 (no) 2003-11-13
NZ528209A (en) 2004-09-24
WO2002092597A1 (en) 2002-11-21
EA005529B1 (ru) 2005-04-28
MXPA03010365A (es) 2004-03-16
EP1390366B1 (en) 2005-08-31
CZ20032917A3 (cs) 2004-07-14
PL366774A1 (en) 2005-02-07
IS6956A (is) 2003-09-15
UA73421C2 (en) 2005-07-15
ES2245731T3 (es) 2006-01-16
US20030149091A1 (en) 2003-08-07
NO20035035L (no) 2003-11-13
BG108344A (bg) 2004-12-30
ATE303386T1 (de) 2005-09-15
CA2446988A1 (en) 2002-11-21
AR035889A1 (es) 2004-07-21
ZA200307234B (en) 2004-09-16
EP1390366A1 (en) 2004-02-25
HRP20030911A2 (en) 2004-02-29
AP2002002522A0 (en) 2002-06-30
EE200300557A (et) 2004-04-15
IL157874A0 (en) 2004-03-28
GT200200081A (es) 2003-04-22
PE20021095A1 (es) 2002-12-14
UY27287A1 (es) 2003-02-28
KR20040008175A (ko) 2004-01-28
DOP2002000390A (es) 2003-03-15
AP1429A (en) 2005-06-13

Similar Documents

Publication Publication Date Title
EG24228A (en) Tartrate salts of 5,8,18-trizatetracyclo[010.3.1.0.0]hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
PL370913A1 (en) Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
HUP0304085A2 (en) The citrate salt of 5,8,14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
HUP0303148A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing the compounds and processes for their preparation
PL374325A1 (en) Succinic acid salts of 5,8,14-triazatetracyclo[10.3.1.0 2,11 .0 4,9 ]-hexadeca-2(11),3,5,7,9,-pentaene and pharmaceutical compositions thereof
ZA200110504B (en) Dietary or pharmaceutical compositions for use for the prevention or treatment of hyperoxaluria.
HUP0401567A3 (en) Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
HUP0400246A3 (en) 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use
HUP0401638A3 (en) Thiopene-amides, thiazolesulfonamides as antineoplastic agents, and pharmaceutical composition containing the same
HUP0401403A3 (en) 2,4-diaminothiazole derivatives, their use and pharmaceutical compositions containing them
HUP0400179A3 (en) 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines, their use and pharmaceutical compositions containing them
HUP0302193A3 (en) 1,4-diazabicyclo[3.2.2]nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation thereof and pharmaceutical compositions containing them
HUP0303155A3 (en) 2-thio-substituted imidazole derivatives, the use thereof and pharmaceutical compositions containing them
IL158587A0 (en) Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof
HUP0402149A3 (en) Water-soluble phenylpyridazine derivatives, their use and pharmaceutical compositions containing the same
HUP0402578A3 (en) 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-carboxamide derivatives, their preparation, their intermediates and pharmaceutical compositions containing the compounds
AU2002308369A1 (en) 1-butane acid derivatives, pharmaceutical compositions containing said derivatives and the use thereof
HUP0201992A3 (en) Indenoindolone derivatives, process for their preparation and pharmaceutical compositions containing the compounds and their use
HUP0402424A3 (en) Imidazoquinoline derivatives, process for their preparation and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees